Wexford Capital LP grew its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 90.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 217,879 shares of the company's stock after acquiring an additional 103,285 shares during the quarter. Wexford Capital LP owned 0.13% of Neumora Therapeutics worth $2,878,000 at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. Amalgamated Bank grew its position in Neumora Therapeutics by 472.8% in the 2nd quarter. Amalgamated Bank now owns 2,910 shares of the company's stock worth $29,000 after purchasing an additional 2,402 shares during the period. Quarry LP purchased a new stake in Neumora Therapeutics in the 2nd quarter worth $98,000. SkyOak Wealth LLC bought a new stake in Neumora Therapeutics during the 2nd quarter valued at approximately $147,000. Principal Financial Group Inc. bought a new stake in shares of Neumora Therapeutics during the second quarter valued at approximately $166,000. Finally, Intech Investment Management LLC purchased a new stake in Neumora Therapeutics in the 3rd quarter worth $175,000. 47.65% of the stock is owned by hedge funds and other institutional investors.
Neumora Therapeutics Stock Up 6.5 %
NASDAQ NMRA traded up $0.63 during midday trading on Friday, hitting $10.29. 1,232,790 shares of the company traded hands, compared to its average volume of 958,246. Neumora Therapeutics, Inc. has a 52 week low of $8.33 and a 52 week high of $21.00. The company's 50-day simple moving average is $12.42 and its 200-day simple moving average is $11.45.
Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.06). During the same quarter last year, the firm posted ($1.14) earnings per share. As a group, analysts expect that Neumora Therapeutics, Inc. will post -1.61 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of research analysts have recently commented on the company. Needham & Company LLC reiterated a "buy" rating and set a $23.00 target price on shares of Neumora Therapeutics in a research report on Wednesday, November 13th. HC Wainwright reissued a "buy" rating and issued a $30.00 price objective on shares of Neumora Therapeutics in a research note on Wednesday, November 13th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $29.00 price objective on shares of Neumora Therapeutics in a research report on Friday, November 22nd. Finally, JPMorgan Chase & Co. lowered shares of Neumora Therapeutics from an "overweight" rating to a "neutral" rating and reduced their target price for the stock from $18.00 to $15.00 in a research report on Tuesday, November 5th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $21.67.
Read Our Latest Research Report on Neumora Therapeutics
Insiders Place Their Bets
In other Neumora Therapeutics news, Director Matthew K. Fust sold 14,049 shares of Neumora Therapeutics stock in a transaction on Friday, October 18th. The stock was sold at an average price of $17.03, for a total value of $239,254.47. Following the sale, the director now owns 20,100 shares in the company, valued at $342,303. The trade was a 41.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Robert A. Lenz sold 5,563 shares of the company's stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $15.01, for a total transaction of $83,500.63. Following the completion of the transaction, the insider now directly owns 322,966 shares in the company, valued at $4,847,719.66. The trade was a 1.69 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,400 shares of company stock valued at $686,361 in the last ninety days. 26.40% of the stock is currently owned by corporate insiders.
About Neumora Therapeutics
(
Free Report)
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Further Reading
Before you consider Neumora Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neumora Therapeutics wasn't on the list.
While Neumora Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
